Testing of a novel inhaled clofazimine (CFZ) dry powder formulation in a mouse model of mycobacterium tuberculosis
Ended Awarded Last action
- Contract number
- 75N93023F00001
- Awardee
-
University Of Texas Medical Branch At Galveston UEI MSPWVMXXMN76 Part of University Of Texas System
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $788,445
Award facts
- Opportunity
-
- 75N93023F00001 Solicitation number
- Contract value 100% obligated
- $788,445.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Galveston, TX 77555, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Change Order | $108,436 | |
| Change Order | $0 | |
| Original award | $680,009 |
About this award
This federal contract award is for testing a novel inhaled clofazimine (CFZ) dry powder formulation in a mouse model of Mycobacterium tuberculosis. The contract, valued at $788,445.00, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to the University of Texas Medical Branch at Galveston (UTMB), a state-controlled institution of higher learning. This contract is a delivery order under UTMB's Preclinical Services for HIV Therapeutics Indefinite Delivery Contract (IDC) with NIAID, which has a total value of $146.3 million. UTMB has extensive experience supporting federal agencies through prime and subcontract research and development efforts, particularly in high-containment laboratory research and infectious disease modeling. The contract does not have a set-aside designation.
Quick answers
Who was awarded contract 75N93023F00001?
75N93023F00001 was awarded to University Of Texas Medical Branch At Galveston by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 1, 2023.
How much is contract 75N93023F00001 worth?
The government has obligated $788,445 on 75N93023F00001.
Is contract 75N93023F00001 an order under another contract?
Yes. 75N93023F00001 is a delivery order under 75N93021D00011, an indefinite delivery contract, on Preclinical Services for HIV Therapeutics.
Was contract 75N93023F00001 competed?
The extent of competition for 75N93023F00001 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award